HONG KONG, Nov 1, 2024 – (ACN Newswire) – JBM (Healthcare) Restricted (“JBM Healthcare” or the “Firm”; Inventory Code: 2161, along with its subsidiaries, the “Group”), a number one branded healthcare merchandise marketer and distributor in Hong Kong, has right this moment introduced a constructive revenue alert. Based mostly on a preliminary evaluate of the unaudited consolidated administration accounts of the Group for the six months ended 30 September 2024 and the data at the moment obtainable to the board of administrators of the Firm, the Group expects to report a rise within the consolidated revenue attributable to shareholders for the six months ended 30 September 2024 (“Consolidated Revenue”) by not lower than 50% as in comparison with that for a similar interval final 12 months.

The numerous enhance in Consolidated Revenue was primarily pushed by the strong gross sales momentum of the Group’s key manufacturers, notably Ho Chai Kung within the branded medicines phase and Po Chai Drugs within the proprietary Chinese language medicines phase. This was additional supported by the sustained progress of the Group’s concentrated Chinese language drugs granules enterprise . This encouraging efficiency displays the Group’s efficient execution of gross sales and advertising methods throughout each offline and on-line channels, capitalising on the expansion potential of branded shopper healthcare merchandise within the markets of Hong Kong, Macau and cities inside the Better Bay Space.

JBM Healthcare has a diversified portfolio spanning branded medicines, proprietary Chinese language medicines, and well being and wellness merchandise. The Group continues to make progress on its strategic priorities, together with increasing e-commerce platforms regionally and cross-border, exploring alternatives in conventional Chinese language medicines for Hong Kong and the Better Bay Space, adapting its product combine to shopper tendencies, leveraging its model administration strengths, and enhancing industrial execution.

For particulars, please discuss with the announcement on HKEX.

About JBM (Healthcare) Restricted (Inventory Code: 2161)

JBM Healthcare is a Hong Kong-based firm that markets and distributes branded healthcare merchandise throughout Better China, Southeast Asia, and different choose nations. The Group is a particular participant within the sector with advertising experience and heritage in prescribed drugs that prioritises product efficacy and high quality to satisfy shoppers’ healthcare wants. As a famend healthcare model operator in Hong Kong, the Group carries a wide-ranging portfolio of branded healthcare merchandise comprising branded medicines, proprietary Chinese language medicines, and well being and wellness merchandise, which embrace well-recognised family manufacturers similar to Po Chai Drugs, Ho Chai Kung Tji Thung San, Contractubex, Mederma for Youngsters, Tong Tai Chung Woodlok Oil, Flying Eagle Woodlok Oil, Saplingtan, Shiling Oil and Konsodona Medicated Oil. JBM Healthcare has been a constituent inventory of the MSCI Hong Kong Micro Cap Index since 27 Could 2021. For extra particulars about JBM Healthcare, please go to: www.jbmhealthcare.com.hk

Matter: Press launch abstract

Supply: JBM (Healthcare) Restricted

Sectors: Healthcare & Pharm

http://www.acnnewswire.com

From the Asia Company Information Community

Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Company Information Community.